Measurements of the parapapillary atrophy zones in en face optical coherence tomography images

To measure the parapapillary atrophy (PPA) area in en face images obtained with swept-source optical coherence tomography (SS-OCT), and to evaluate its relationship to glaucoma, myopia, and age in non-highly myopic subjects. Retrospective, cross-sectional study. Fifty eyes of 30 subjects with open-a...

Full description

Saved in:
Bibliographic Details
Published inPLOS ONE Vol. 12; no. 4; p. e0175347
Main Authors Miki, Atsuya, Ikuno, Yasushi, Weinreb, Robert N., Yokoyama, Junko, Asai, Tomoko, Usui, Shinichi, Nishida, Kohji
Format Journal Article
LanguageEnglish
Published United States Public Library of Science (PLoS) 17.04.2017
Public Library of Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To measure the parapapillary atrophy (PPA) area in en face images obtained with swept-source optical coherence tomography (SS-OCT), and to evaluate its relationship to glaucoma, myopia, and age in non-highly myopic subjects. Retrospective, cross-sectional study. Fifty eyes of 30 subjects with open-angle glaucoma (G group) and forty-three eyes of 26 healthy control subjects (C group). Eyes with high myopia (spherical equivalent refractive error ≤ -8 diopters or axial length ≥ 26.5 mm) were excluded. Mean age ± standard deviation was 59.9 ± 12.4 years. The beta zone and the gamma zone PPA areas were measured in en face images reconstructed from three-dimensional SS-OCT images. Relationship between the PPA areas and patient characteristics such as glaucoma, axial length, and age was statistically evaluated using multivariate mixed-effects models. Areas of the beta zone and the gamma zone PPA measured on en face OCT images. Average ± standard deviation area of the beta and the gamma zone was 0.64 ± 0.79 and 0.16 ± 0.30 mm2, respectively. In multivariate models, the gamma zone significantly correlated with axial length (P = 0.001) but not with glaucoma (P = 0.944). In contrast, the beta zone significantly correlated with age (P = 0.0249) and glaucoma (P = 0.014). En face images reconstructed from 3D SS-OCT data facilitated measurements of the beta and the gamma PPA zones even in eyes with optic disc distortion. The OCT-defined beta zone is associated with glaucoma and age, whereas the gamma zone correlated with myopia but not with glaucoma. This study confirmed the clinical usefulness of OCT-based classification of the PPA zones in distinguishing glaucomatous damage of the optic nerve from myopic damage in non-highly myopic eyes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: Atsuya Miki: Honoraria/lecture fees: Pfizer Japan (Tokyo, Japan), Santen Pharmaceutical (Osaka, Japan), Otsuka Pharmaceutical (Tokyo, Japan), Alcon Japan (Tokyo, Japan), R-Tech Ueno (Tokyo, Japan) Yasushi Ikuno: Research Support: Tomey (Nagoya, Japan), Topcon (Tokyo, Japan); Consultant: Bayer Yakuhin (Osaka, Japan), Novartis Pharma (Tokyo, Japan) Robert N. Weinreb: Research support: Carl Zeiss Meditec Inc (Dublin, California), Genentech (San Francisco, California), Heidelberg Engineering (Heidelberg, Germany), Nidek Co (Gamagori, Japan), Novartis AG (Basel, Switzerland), Optovue Inc (Fremont, California), Topcon (Tokyo, Japan); Consultant: Alcon Laboratories (Fort Worth, Texas), Allergan (Irvine, California), AqueSys Inc (Taipei, Taiwan), Bausch&Lomb (Rochester, New York), Carl Zeiss Meditec Inc (Dublin, California), Topcon (Tokyo, Japan). Kohji Nishida: Research Support: Otsuka Pharmaceutical (Tokyo, Japan), AMO Japan (Tokyo, Japan), Topcon (Tokyo, Japan), Menicon (Nagoya, Japan), Wakamoto (Tokyo, Japan), Senju Pharmaceutical (Osaka, Japan), Rohto Pharmaceutical (Osaka, Japan), Santen Pharmaceutical (Osaka, Japan), Novartis Pharma (Tokyo, Japan), Alcon Japan (Tokyo, Japan), Pfizer Japan (Tokyo, Japan), Hoya (Tokyo, Japan), Bayer Yakuhin (Osaka, Japan), MSD Japan (Tokyo, Japan), Kowa Pharmaceuticals (Nagoya, Japan); Honoraria/lecture fees: Senju Pharmaceutical (Osaka, Japan), Pfizer Japan (Tokyo, Japan), Santen Pharmaceutical (Osaka, Japan), Otsuka Pharmaceutical (Tokyo, Japan), Novartis Pharma (Tokyo, Japan), Alcon Japan (Tokyo, Japan), Pfizer Japan (Tokyo, Japan), Hoya (Tokyo, Japan), Boehringer Ingelheim Japan (Tokyo, Japan), Bayer Yakuhin (Osaka, Japan), Kowa Pharmaceuticals (Nagoya, Japan), SEED (Tokyo, Japan), Chuo Sangio (Hyogo, Japan), Johnson & Johnson Japan (Yokohama, Japan). The following authors have no financial disclosures: Junko Yokoyama, Tomoko Asai, Shinichi Usui. We declare that competing interests do not alter our adherence to PLOS ONE policies on sharing data and materials.
Conceptualization: AM YI RNW.Data curation: AM YI JY TA SU.Formal analysis: AM YI RNW.Investigation: AM YI JY TA SU.Methodology: AM YI RNW KN.Project administration: AM YI KN.Resources: AM YI KN.Software: AM.Supervision: YI KN.Validation: AM YI RNW JY TA SU KN.Visualization: AM.Writing – original draft: AM YI RNW.Writing – review and editing: AM YI RNW JY TA SU KN.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0175347